CHMP2B

Across TCGA pan-cancer cohorts, CHMP2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHMP2B data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CHMP2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHMP2B expression acts as an unfavorable survival marker.

SKCM, CESC, and TGCT are the cancer types where CHMP2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.194	0.784	<.001	18	view →
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
TGCT	DFS	Median	All	0.082	0.837	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHMP2B–SKCM (OS)

Open the SKCM breakdown →